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Mitochondria are the principal producers of energy in higher cells. Mitochondrial dysfunction is implicated in a variety of human diseases,
including cancer and neurodegenerative disorders. Effective medical therapies for such diseases will ultimately require targeted delivery of
therapeutic proteins or nucleic acids to the mitochondria, which will be achieved through innovations in the nanotechnology of intracellular
trafficking. Here we describe a liposome-based carrier that delivers its macromolecular cargo to the mitochondrial interior via membrane fusion.
These liposome particles, which we call MITO-Porters, carry octaarginine surface modifications to stimulate their entry into cells as intact vesicles
(via macropinocytosis). We identified lipid compositions for the MITO-Porter which promote both its fusion with the mitochondrial membrane
and the release of its cargo to the intra-mitochondrial compartment in living cells. Thus, the MITO-Porter holds promise as an efficacious system
for the delivery of both large and small therapeutic molecules into mitochondria.
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Mitochondrial dysfunction has recently been implicated in a
variety of diseases, including cancer, Alzheimer's disease, Par-
kinson's disease, and diabetes mellitus [1,2]. Although therapies
for these diseases are desired, strategies designed to complement
mitochondrial dysfunction are rare [3–6]. Targeted delivery of
an engineered gene or gene product to the nucleus or mito-
chondrion is an essential first step towards therapeutic restora-
tion of a missing cellular function [3,7]. For example, a nuclear
localization signal (NLS) peptide can be used to guide a protein
into the nucleus [8]. However, the same NLS does not work as
such when attached to a large circular DNA (i.e., plasmid DNA;⁎ Corresponding author. Tel.: +81 11 706 3919; fax: +81 11 706 4879.
E-mail address: harasima@pharm.hokudai.ac.jp (H. Harashima).
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doi:10.1016/j.bbamem.2007.11.002pDNA) [9,10].We also faced this problem in the case of delivery
of molecules to mitochondria: conjugation of a mitochondrial
targeting signal (MTS) peptide to exogenous proteins and small
linear DNAs was found to aid their delivery to the mitochondria
[11–15], but this strategy did not work for pDNA. Because large
molecules such as pDNA and folded protein do not readily pass
through the mitochondrial membrane, they cannot be delivered
into mitochondria easily [16,17].
Here, we describe MITO-Porter, a liposome-based carrier
that introduces cargos into mitochondria via a membrane fusion
mechanism (Fig. 1). The first barrier to intracellular targeting is
the plasma membrane. The MITO-Porter surface carries octa-
arginine (R8) moieties at high density so that the particles are
internalized bymacropinocytosis rather than by clathrin-mediated
endocytosis as occurs in the case of cationic liposomes [18]. We
have shown that high-density R8-modified liposomes (R8-LPs)
Fig. 1. A new concept for delivery of macromolecules into mitochondria using MITO-Porter. MITO-Porter is surface-modified with a high density of octaarginine
(R8), which can be internalized by cells via macropinocytosis (1st step). R8 can escape from macropinosomes to the cytosol, which prevents lysosomal degradation
(2nd step). MITO-Porter in the cytosol can bind to mitochondria via electrostatic interactions with R8 (3rd step). Encapsulated compounds are delivered to the intra-
mitochondrial compartment via membrane fusion with the help of sphingomyelin (SM) or phosphatidic acid (PA), which were determined to be fusogenic lipids with
the mitochondrial membrane (4th step). OM, outer membrane; IMS, intermembrane space; IM, inner membrane.
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keeping the encapsulated compounds intact, while low density
R8-LPs are taken up via clathrin-mediated endocytosis and de-
graded by lysosomal enzymes [18]. Upon release from the
macropinosomes, MITO-Porter then binds to the mitochondrial
membrane via electrostatic interactions, which induces fusion
between the MITO-Porter and mitochondrion (Fig. 1).
The purpose of this study was to validate the principle of our
mitochondrial delivery system based on membrane fusion. We
first screened for liposomes that efficiently fuse with isolated rat
liver mitochondria. This was achieved by varying the lipid
composition of a panel of liposomes and monitoring membrane
fusion by fluorescence resonance energy transfer (FRET) ana-
lysis. Two highly fusogenic lipid compositions were identified
and they form the basis of the MITO-Porter. Green fluorescence
protein (GFP) was used as a model macromolecule, which per-
mitted us to check its delivery to mitochondria by confocal laser
scanning microscopic analysis. In addition, membrane fusion
between the MITO-Porter and mitochondria in living cells was
evaluated by FRET analysis using a spectral imaging fluor-
escent microscopy system.
2. Materials and methods
2.1. Materials
E. coli strain BL21 (DE3) [F−, ompT, hsdSB (rB
− mB
− ), gal, dcm (DE3)] was
purchased from Stratagene (La Jolla, CA, USA). Oligonucleotides were pur-
chased from Sigma Genosys Japan (Ishikari, Japan) in purified form. Adult male
Wistar rats (6–10 weeks old) were purchased from Sankyo Labo Service
(Sapporo, Japan). Cholesterol (Chol), 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE), 7-nitrobenz-2-oxa-1,3-diazole labeled DOPE (NBD–
DOPE), and rhodamine–DOPE were purchased from Avanti Polar lipids (Ala-
baster, AL, USA). Egg yolk phosphatidyl choline (EPC) was obtained from
NipponOil and Fats Co. (Tokyo, Japan). Cholesteryl hemisuccinate (5-cholesten-
3-ol 3-hemisuccinate; CHEMS), cardiolipin (CL), phosphatidic acid (PA),
phosphatidyl glycerol (PG), phosphatidyl inositol (PI), phosphatidyl serine (PS),
sphingomyelin (SM), and Gold Colloid (8–12nm in diameter; code G-1527)
were purchased from Sigma (St. Louis, MO, USA). Stearyl octaarginine (STR-
R8) was kindly supplied by Dr. S. Futaki (Kyoto University, Japan). HeLa human
cervix carcinoma cells were obtained from RIKEN Cell Bank (Tsukuba, Japan).
Dulbecco's modified Eagle medium (D'MEM) and fetal bovine serum (FBS)
were purchased from Invitrogen Corp. (Carlsbad, CA, USA). All other chemicals
used were commercially available reagent-grade products.
2.2. Preparation of green fluorescent protein
GFP for use as a model macromolecule was prepared as previously des-
cribed [19]. The purified protein was analyzed by SDS-PAGE. Protein con-
centrations were determined with a BCA Protein Assay Kit (Pierce; Rockford,
IL, USA).
2.3. Liposome preparation
Liposomes were prepared with various lipid compositions by a hydration
method (Table 1). Lipid stocks were prepared in chloroform and stored at −20 °C
until used. Lipid films were formed on the bottom of a glass tube by evaporating
the chloroform solution. To generate empty vesicles, 0.25 mL of mitochondrial
isolation buffer [MIB: 250 mM sucrose, 2 mMTris–HCl, pH 7.4] was applied to
137.5 nmol of dried lipid film. After incubation for 10 min for hydration, the
suspensions were sonicated using a bath-type sonicator (85W, Aiwa Co., Tokyo,
Japan) for 15 s. An STR-R8 solution (10 mol% of lipids) was then added to the
suspension, followed by incubation for 30 min at room temperature to attach the
R8 to the surface of the liposome. The diameter was measured by a quasi-elastic
light scatteringmethod, and the zeta potential was determined electrophoretically
using an electrophoretic light scattering spectrophotometer (ELS-8000, Otusuka
Table 1
Characteristics of liposomes
Liposome
type
Liposome composition
(molar ratio)
Lipid X component and diameter of liposomes (nm)
Anionic lipids Neutral lipids
CLb PI PG PS PA CHMES SM Chol
R8-DOPE-LP DOPEa:lipid X:STR-R8 (9:2:1) 234±43 224±32 224±25 266±64 261±59 335±27 264±90 260±28
DOPE-LP DOPE:lipid X (9:2) 318±79 268±33 246±6 289±42 232±56 315±28 223±41 309±29
R8-EPC-LP EPC:lipid X:STR-R8 (9:2:1) 229±52 218±58 225±38 268±70 217±41 261±34 227±27 279±41
EPC-LP EPC:lipid X (9:2) 259±69 263±87 307±128 331±72 212±56 336±760 268±32 392±133
aDOPE, 1,2-dioleoyl-sn-glycero-3-phosphatidyl ethanolamine; EPC, egg yolk phosphatidyl choline; STR-R8, stearyl octaarginine.
bCL, cardiolipin; PI, phosphatidyl inositol; PG, phosphatidyl glycerol; PS, phosphatidyl serine; PA, phosphatidic acid; CHEMS, Cholesteryl hemisuccinate
(5-cholesten-3-ol 3-hemisuccinate); SM, sphingomyelin; Chol, cholesterol.
Each value is represented by the mean±S.D., n=3.
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Gold Colloid (gold concentration; 0.8 A520) were encapsulated in an aqueous
phase as model macromolecules.
To estimate the encapsulation efficiency, GFP encapsulated in liposome
containing rhodamine–DOPE was separated from free GFP by centrifugation at
113,000 g for 45 min at 4 °C and washed twice in a MIB [20]. The liposome-
encapsulated GFP was determined by measuring the fluorescence intensity
(excitation at 488 nm and emission at 507 nm) after treatment with lysis buffer
(Promega; WI, USA). The amount of the lipid was determined by measuring the
fluorescence intensity of rhodamine–DOPE (excitation at 550 nm and emission
at 590 nm). The encapsulation efficiency was calculated as follows:
encapsulation efficiency kð Þ ¼ recovered GFP= recovered lipidð Þ
= applied GFP=applied lipidð Þ  100
ð1Þ
2.4. Isolation of mitochondria from rat liver
Mitochondria were isolated from livers obtained from adult male Wistar rats
(6–8 weeks old) essentially as described previously [21]. Rats were sacrificed
and the livers were removed after bleeding largely subsided, and then placed in
approximately 20 mL of ice-cold MIB per 10 g of liver. All subsequent steps
were carried out on ice. Livers were chopped into small pieces and the sus-
pension was homogenized in a glass homogenizer (50 mL capacity) with a
pestle. Three complete cycles up and down with the pestle were made. The
pestle was motor-driven and operated at approximately 550 rpm. The homo-
genate was diluted approximately 1:3 with MIB and centrifuged at 800 ×g for
5 min. The supernatant was transferred into ice-cold tubes and centrifuged at
7500 ×g for 10 min. The pellets were washed twice with MIB, which contained
EDTA, and once further with EDTA-free MIB. Concentrations of mitochondrial
proteins were determined using a BCA protein assay kit. Purity of the mito-
chondrial preparation was greater than 90% as judged by electron microscopy
[22], and the respiration control index of mitochondria was determined to be
4.5–6 using a Clark oxygen-electrode (YSI 5331;Yellow Springs Instrument
Co., Yellow Springs, OH, USA), indicating that the mitochondria were intact
and respiring. All animal protocols were approved by the institutional animal
care and research advisory committee at the Faculty of Pharmaceutical Sciences,
Hokkaido University, Sapporo, Japan.
2.5. Membrane fusion assay using FRET analysis
The membrane fusion activity of liposomes with mitochondria was assessed
by FRETas described previously [23–25]. In this experiment, liposomes labeled
with both 1 mol% NBD–DOPE and 0.5 mol% rhodamine–DOPE were used. A
10-μL aliquot of labeled liposome (lipid concentration, 550 μM) was added to
mitochondria isolated from rat liver (0.9 mg of mitochondrial protein/mL) in
90 μL of MIB, and incubated for 30 min at 25 °C. After incubation, energy
transfer was assessed by measuring the fluorescence intensity (excitation at
470 nm and emission at 530 nm).
Membrane fusion between the labeled liposomes and the mitochondria will
lead to the diffusion of NBD and rhodamine into the lipid membranes, whichcauses reduction of energy transfer, resulting in an increase in fluorescence
intensity at 530 nm. The maximum fluorescence was defined as the fluorescence
of liposomes when dissolved in Triton X-100 (final concentration of 0.5%).
Fusion activity (%) was estimated by the reduction in the level of energy transfer
in accordance with membrane fusion, and was calculated as follows:
fusion activity kð Þ ¼ FF0ð Þ= FmaxF0ð Þ  100 ð2Þ
where F, F0, Fmax represent the fluorescence intensity of labeled liposome after
incubation with mitochondria, the fluorescence intensity of labeled liposome
after incubation without mitochondria, and the maximum fluorescence intensity
after the Triton X-100 treatment, respectively.
2.6. Delivery of GFP to isolated rat liver mitochondria and detection
of GFP in mitochondria
A 100-μL aliquot of GFP (125 ng/μL) or GFP encapsulated in R8-LP was
individually added to 1 mL of isolated rat liver mitochondria solution (10 mg of
mitochondrial protein/mL) to a final lipid concentration of 50 μM and incubated
for 30 min at 25 °C. The suspension was centrifuged at 16,000 ×g for 10 min at
4 °C to precipitate the mitochondria, and the supernatant was removed. The
pellet was washed twice with MIB at 4 °C, and then resuspended in 100 μL of
isolation buffer [IB: 70 mM sucrose, 220 mM D-mannitol, 0.5 mg/ml bovine
serum albumin (essential fatty acid free, Sigma), 2.0 mM HEPES, pH 7.4].
After incubation, mitochondria were subfractionated into outer membrane
(OM) and intermembrane space (IMS) fractions by digitonin treatment followed
by differential centrifugation [26]. In brief, an equal volume of IB with 1.25%
digitonin (NACALAI TESQUE, INC; Kyoto, Japan) was added to the
mitochondria solution and mixed gently for 15 min at 4 °C. The suspension
was diluted by the addition of three volumes of IB and then centrifuged at
10,000 ×g for 10 min at 4 °C. The pelleted fraction was resuspended in IB and
then centrifuged again at 10,000 ×g for 10 min at 4 °C. The combined
supernatant fluid was centrifuged at 144,000 ×g for 60 min at 4 °C. The pelleted
fraction was resuspended in 100 μL of IB to obtain the OM fraction. The
supernatant was centrifuged again at 144,000 ×g for 60 min at 4 °C and the
resulting supernatant was used as the IMS fraction. Protein concentrations of
both the OM and IMS fractions were determined using a BCA protein assay kit.
The protein concentrations were adjusted to 1 mg/mL and stored at −80 °C prior
to use. GFP was detected by Western blotting.
2.7. Assessment of degradation of GFP in the mitochondrial
intermembrane space
A 10 μL aliquot of GFP (10 ng/μL) was added to 90 μL of either the IMS
fraction (1 mg/mL protein concentration) or IB, and then incubated for 30 min at
25 °C. After incubation, the resulting suspensions were stored at −80 °C prior to
use. GFP was subject to Western blotting.
A 5-μL aliquot of GFP (125 ng/μL) was added to 50 μL of either the IMS
fraction (1mg/mL) or IB, and incubated for 30min at 25 °C. After the incubation,
an equal volume of IBwas added to the resulting suspension and the fluorescence
intensity of GFP measured (excitation at 474 nm and emission at 509 nm).
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An equal volume of the sample was mixed with loading buffer (100 mM
Tris–HCl (pH 6.8), 4% SDS, 12% 2-mercaptoethanol, 20% glycerol, 0.05%
bromophenol blue), and then subjected to 15% SDS-PAGE. After electrophor-
esis, the proteins were electroblotted onto a Polyvinylidene Fluoride membrane
(NIPPON Genetics Co., Ltd; Tokyo, Japan). Antibodies against the N-terminus
of GFP derived from rabbit (Sigma) were used at 1:1000 to 1:2500 dilutions.
GFP was further detected using secondary HRP-conjugated anti-rabbit
antibodies (GE Healthcare UK Ltd, England) at a 1:1000 dilution.
2.9. MITO-Porter transduction and staining of mitochondria for
confocal laser scanning microscopy analyses
HeLa cells (4×104 cells/mL) were cultured in 35 mm glass base dishes
(IWAKI, Tokyo, Japan) with D'MEM, which contained 10% FBS, under 5%
CO2/air at 37 °C for 24 h. The cells were washed with ice-cold phosphate-
buffered saline [PBS (−)] and incubated in serum-free medium with R8-LP.
After a 1-h incubation under 5% CO2/air at 37 °C, the cells were washed with
ice-cold PBS (−), and further incubated in mediumwith 10% serum for 1 h in the
absence of R8-LP. After incubation, MitoFluor Red 589 (Molecular Probes;
Eugene, OR, USA) was applied to the medium at a final concentration of
100 nM to stain the mitochondria. After incubation for 20 min, the cells were
washed with ice-cold PBS (−) and then observed by confocal laser scanning
microscopy (LSM510 or LSM510 META; Carl Zeiss Co. Ltd., Jena, Germany).
2.10. Intracellularobservation using confocal laser scanningmicroscopy
R8-LPs encapsulating GFP or labeled with 1 mol% NBD–DOPE were
incubated with HeLa cells (final lipid concentration, 13.5 μM) to observe the
intracellular trafficking of encapsulated GFP (Fig. 4A) or the carriers themselves
(Fig. 4B). The cells were excited by 488 nm and 568 nm light from an Ar/Kr
laser. A series of images were obtained using an LSM510 with a water
immersion objective lens (Achroplan 63x/NA=0.95) and a dichroic mirror
(HFT488/568). The two fluorescence detection channels (Ch) were set to the
following filters: Ch1: LP585 (red); Ch 2: BP 505–550 (green).
2.11. Intracellular observation of Gold Colloid encapsulated in
MITO-Porter using transmission electron microscopy
HeLa cells (1×105 cells/mL) were cultured in 100-mm tissue culture dishes
with D'MEM, which contained 10% FBS, under 5% CO2/air at 37 °C for 24 h.
The cells were washed with ice-cold PBS (−) and incubated in 5 mL of serum-
free medium, which contained R8-LP encapsulating Gold Colloid to a final lipid
concentration of 50 μM. After a 1-h incubation under 5% CO2/air at 37 °C, the
cells were washed 3 times with ice-cold PBS (−), and further incubated in
medium with 10% serum for 1 h in the absence of R8-LP.
Transmission electron microscopy analysis of cells treated with various
liposomes was carried out essentially as described previously [27,28]. Cells
treated with liposomes were detached with 0.05% trypsin–0.03% EDTA and
then pelleted by centrifugation at 200 ×g for 3 min. After centrifugation, the cells
were fixed in cacodylate buffer (0.05 M cacodylate, pH 7.4) supplemented with
250 mM sucrose and 1% glutaraldehyde. After a 1-h incubation at 4 °C, the
fixed cells were again centrifuged at 200 ×g for 5 min and then postfixed in
cacodylate buffer supplemented with 0.5% OsO4. After a 1-h incubation at 4 °C,
the cells were dehydrated in a graded series of ethanol and embedded in TAAB
EPON 812 RESIN (TAAB Laboratories Equipment Ltd; Berkshire, England).
Ultrathin sections were stained with uranyl acetate and lead citrate and examined
by transmission electron microscopy with a Hitachi H-800MT electron
microscope (Hitachi High-Tech Science Systems Corporation; Ibaraki, Japan).
2.12. Evaluation of membrane fusion in living cells using spectral
imaging fluorescent microscopy
R8-LPs were prepared with 1 mol% NBD–DOPE (excitation at 460 nm and
emission at 534 nm) and 0.5 mol% rhodamine–DOPE (excitation at 550 nm andemission at 590 nm) as a donor and an acceptor of FRET, respectively. The dual-
labeled liposomes were incubated with HeLa cells (final lipid concentration,
5.4 μM). Mitochondria were additionally stained with MitoFluor Red 589
(excitation at 588 nm and emission at 622 nm). The cells were observed using an
LSM510META equippedwith an oil-immersion objective lens (Plan-Apochromat
63x/NA=1.4). To evaluate membrane fusion between the carriers and mitochon-
dria, NBD was excited by light (488 nm) derived from an argon laser. Emitted
light filtered through a dichroic mirror (HFT488) was spectroscopically analyzed
(510–630 nm) as shown in Fig. 6 (A,D). Through the spectra ranges used in the
analysis, background fluorescence derived from the emission from rhodamine
and MitoFluor Red 589 was negligible when they were excited at 488 nm (data
not shown). Fluorescence spectra of R.O.I. (region of image) were selected
Fig. 6 (A,D) and the emission at each wavelength were normalized to the rho-
damine peak fluorescence intensity (emission at 590 nm) as shown in Fig. 6 (C,F).
To identify the localization of liposomes on the mitochondria, images were
further obtained by spectral images ranging from 570 to 630 nm with a He/Ne
laser (543 nm) using a dichroic mirror (HFT UV/488/543/633) as shown in
Fig. 6 (B,E). Liposomes (yellow) and mitochondria (red) can be clearly dis-
tinguished since the emission spectral peak of MitoFluor Red 589 was detected
at the far-red region (emission at 622 nm) compared with that of rhodamine
(emission at 590 nm).
To further evaluate membrane fusion of the carriers, the relative intensity of
fluorescence on and outside the mitochondria was estimated (Fig. 7). Relative
intensity represents reduction of energy transfer as a function of membrane
fusion. Based on images, when the carriers were excited by light of 488 nm, the
relative intensity was calculated by as follows:
relative intensity ¼ F530=F590 ð3Þ
where F530 and F590 represent the fluorescence intensity of carriers at 530 nm
and 590 nm, respectively.
3. Results
3.1. Screening for fusogenic liposomes to the mitochondrial
membrane
To deliver cargos into mitochondria in our strategy, the
liposomes must fuse with the mitochondrial membrane.
Although the R8-LPs composed of DOPE and CHEMS can
deliver pDNA to the nucleus efficiently [29], these lipids may
not be the best lipid composition for mitochondria. Therefore,
we screened liposomes with different lipid compositions for
their ability to fuse with the mitochondrial membrane. Table 1
summarizes the sizes of the liposomes. The diameters were
comparable (approximately 200–300 nm). Overall, the zeta
potentials of the neutral lipid-containing liposomes, the anionic
lipid-containing liposomes, and the R8-LPs were approximately
0 mV, −50 mV, and +50 mV, respectively.
These liposomes were incubated with isolated rat liver
mitochondria and their fusogenic activity was measured using
FRET. As shown in Fig. 2, R8-LPs composed of DOPE (R8-
DOPE-LPs), which is a fusogenic lipid commonly used in drug
delivery, showed higher fusogenic activities than R8-LPs
composed of egg yolk phosphatidyl choline (R8-EPC-LPs). In
the absence of R8 surface modification, binding of the lipo-
somes to mitochondria is considerably reduced, suggesting that
a strong electrostatic binding between R8-LPs and mito-
chondria stimulates the fusogenic activity of liposomes, and
especially those containing DOPE. R8-DOPE-LPs also contain-
ing SM or PA exhibited the highest fusion activities among the
lipids examined. Based on these results, we named the R8-
DOPE-LPs containing either SM or PA as MITO-Porters.
Fig. 2. Screening of fusogenic lipid composition with the mitochondrial membrane. Labeled liposomes were incubated with isolated rat liver mitochondria for 30 min at
25 °C. After incubation, energy transfer was assessed by the fluorescence intensity. Fusion activities (%) of DOPE-LP (A) and EPC-LP (B) were calculated in terms of
reduction of FRETas described in theMaterials and methods section. Data are presented as a mean of triplicates. Red bars, R8-LP; blue bars, unmodified liposome. DOPE,
1,2-dioleoyl-sn-glycero-3-phosphatidyl ethanolamine; EPC, egg yolk phosphatidyl choline; CL, cardiolipin; PI, phosphatidyl inositol; PG, phosphatidyl glycerol; PS,
phosphatidyl serine; PA, phosphatidic acid; CHEMS, cholesteryl hemisuccinate (5-cholesten-3-ol 3-hemisuccinate); SM, sphingomyelin; Chol, cholesterol. Data are
represented by the mean±S.D. (n=3).
Fig. 3. Mitochondrial delivery of GFP with MITO-Porter. A, GFP was detected
in isolated rat liver mitochondria using Western blotting as follows: lanes 1,2,
GFP alone; lanes 3,4, MITO-Porter (SM) [R8-DOPE/SM-LP]; lanes 5,6, MITO-
Porter (PA) [R8-DOPE/PA-LP]; lanes 7,8, R8-EPC/SM-LP; lanes 9,10, R8-
EPC/PA-LP. Bands observed at 33 kDa and 28 kDa represent the full-length
GFP (lanes 3,5,7,9) and the fragment of GFP (lanes 4,6), respectively. OM
(lanes 1,3,5,7,9) and IMS (lanes 2,4,6,8,10) indicate outer membrane fraction
and intermembrane space fraction, respectively. B, GFP was added either to the
IMS (lane 1) or to isolation buffer (IB) (lane 2) and then incubated at 25 °C for
30 min (final GFP concentration, 1 ng/μL). After incubation, a 2.5 μL aliquot of
each sample was subjected to Western blotting. C, Comparison of the
fluorescence intensity between full-length GFP and the fragment of GFP.
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mitochondria
We next examined whether the MITO-Porters could deliver
macromolecules to the mitochondria by passing through the
OM of mitochondria. GFP was encapsulated into the MITO-
Porter and incubated with isolated rat liver mitochondria. After
the mitochondria were fractionated into OM and IMS fractions,
GFP was detected by Western blotting. As shown in Fig. 3A, in
the case of MITO-Porter, GFP was detected in both the OM and
IMS fractions (lanes 3–6), while in the case of R8-EPC-LP (low
fusion activity), GFP was detected only in the OM fraction
(lanes 7–10). These results indicated that MITO-Porter could
deliver macromolecules into mitochondria, while R8-EPC-LP
could only bind to the OM and failed to deliver GFP into
mitochondria. GFP was not detected in either the OM or IMS
fractions when GFP alone was incubated with isolated rat liver
mitochondria (Fig. 3A, lanes 1,2). This result suggested that the
packaging of GFP in MITO-Porter is an important process,
although the encapsulation efficiency of MITO-Porter was not
high (approximately 1%).
Unexpectedly, the molecular weight of GFP detected in the
IMS fraction (28 kDa) was smaller than that of the full-length
molecule (33 kDa), which suggested the possibility that GFP
was cleaved by a protease(s) in the IMS. To test this, we
incubated purified GFP with either the IMS fraction or IB, and
then subjected the reactions to Western blotting. As predicted,
the molecular weight of GFP incubated in the IMS fraction
was 28 kDa, whereas it remained intact when incubated in IB
(Fig. 3B). Furthermore, it is noteworthy that the cleavage site
must be far from the active center of GFP (25 kDa) [30],
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(Fig. 3C). These results support the assertion that the MITO-
Porter delivered its GFP cargo to the IMS by passing through
the OM.
3.3. Intracellular observation of MITO-Porters by confocal
laser scanning microscopy
The ability of MITO-Porter to deliver macromolecules into
mitochondria was examined in living HeLa cells using confocal
laser scanning microscopy. GFP, which is an aqueous phase
marker, was encapsulated in MITO-Porter. When living cells
were treated with GFP alone, we could not observe GFP in
those cells (data not shown). In the case of MITO-Porter, GFP
(green) was seen to co-localize with mitochondria (stained red
with MitoFluor Red 589), observed as a yellow signal in the
merged images (Fig. 4A (a),(b)). Yellow clusters were seen in
several different cells (see Supplementary data, Fig. S1). Ap-
proximately 10% of the cells possessed GFP-positive mito-
chondria. On the other hand, little co-localization was observed
in the case of the R8-EPC-LP control carrier (Fig. 4A (c)). No
co-localization between GFP and mitochondria in images from
at least 30 different cells was observed (data not shown). We
expected to see a diffused GFP signal in mitochondria in the
case of the MITO-Porter; however, we actually observed yellow
clusters (Fig. 4A (a),(b)). These results could be explained by
the fact that mitochondria are compartmentalized in living cellsFig. 4. Intracellular observation of MITO-Porter using confocal laser scanning micros
PA-LP] (b), and R8-EPC/Chol-LP (c) encapsulating GFP as an aqueous phase marke
with HeLa cells at 37 °C for 1 h. After the medium had been replaced, the cells were f
with MitoFluor Red 589 prior to observation by confocal laser scanning microscop
respectively. Scale bar, 10 μm.[31] and GFP delivered by MITO-Porter may not be able to
diffuse into other compartments.
Similar results were also found for the intracellular distri-
bution of the carriers themselves (Fig. 4B). In the case of the
MITO-Porter, several yellow clusters were observed (Fig. 4B
(a),(b)), indicating that the MITO-Porters (green) are co-
localized with mitochondria (red). These results suggested that
the lipid of the MITO-Porter had accumulated in mitochondria.
In contrast, in the case of R8-EPC-LP, only green clusters were
observed (Fig. 4B (c)). It is likely that R8-EPC-LPs failed to fuse
with the mitochondrial membrane, even though they could be
delivered close to the mitochondria. Furthermore, when MITO-
Porter was added to homogenate from HeLa cells, approxi-
mately 20% of the MITO-Porter bound to mitochondria while
most remained in the cytosol fraction (data not shown). This
result was consistent with that of the confocal laser scanning
microscopy analyses, as shown in the Fig. 4, where some but not
all of the MITO-Porters accumulated at mitochondria within
cells.
3.4. Observation of macromolecule delivery to mitochondria in
living cells using transmission electron microscopy
Transmission electron microscopy analysis was also per-
formed to provide evidence that MITO-Porter can deliver
macromolecules into mitochondria of living cells. Colloidal
gold particles with a diameter of approximately 10 nm werecopy. MITO-Porter (SM) [R8-DOPE/SM-LP] (a), MITO-Porter (PA) [R8-DOPE/
r (A), or labeled with NBD–DOPE as a tracer of the carrier (B) were incubated
urther incubated for 1 h in the absence of the carriers. Mitochondria were stained
y. The clusters present in the mitochondria and cytosol are indicated as I or II,
Fig. 5. Transmission electron microscopy observation of mitochondrial delivery in living cells. MITO-Porter (SM) [R8-DOPE/SM-LP] (A) and R8-EPC/SM-LP (B)
encapsulating Gold Colloid (8–12 nm in diameter) as a model macromolecule were incubated with HeLa cells at 37 °C for 1 h. After the medium had been replaced,
the cells were further incubated for 1 h in the absence of the carriers, and then the cells were observed by transmission electron microscopy as described in the Materials
and methods section. Mt indicates mitochondria. Scale bars, 100 nm.
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MITO-Porter, and R8-EPC-LP was used as a control. MITO-
Porter successfully delivered colloidal gold particles into
mitochondria while R8-EPC-LP did not (Fig. 5). These results
provide further support that MITO-Porter is able to deliver large
molecular weight cargoes into the intra-mitochondrial compart-
ment in living cells.Fig. 6. Membrane fusion evaluation between MITO-Porter and mitochondria in living
Porter (SM) [R8-DOPE/SM-LP] (A–C) and R8-EPC/SM-LP (D–F) were prepared w
HeLa cells followed by observation using confocal laser scanning microscopy as des
observed in the case of excitation at 488 nm to evaluate membrane fusion by FRET. (
identify the localization of liposomes (yellow color) and mitochondria (red color). (C
and the emission were normalized to the rhodamine peak fluorescence intensity. The s
respectively. In the non-fusogenic state, emission energy of NBD (donor) is transferre
intensity of NBD at 530 nm was minimized. Lipid mixing by membrane fusion betwe
the donor and acceptor; this results in a reduction of FRET and an increase in the fl3.5. Evaluation of membrane fusion with mitochondria in
living cells using spectral imaging fluorescent microscopy
To obtain more direct evidence that MITO-Porter can deliver
macromolecules into mitochondria via membrane fusion,
we performed FRET analysis in living cells using a spectral
imaging fluorescence microscopy system [32]. FRETanalysis iscells by FRET analysis using spectral imaging fluorescence microscopy. MITO-
ith both NBD–DOPE and rhodamine–DOPE. Next, they were incubated with
cribed in the Materials and methods section. (A,D) Spectral image figures were
B,E) Spectral image figures were observed in the case of excitation at 543 nm to
,F) Fluorescence spectra of R.O.I. (region of image) were selected from A and D
pectra present on and outside the mitochondria are indicated as red or blue lines,
d to the excitation energy of rhodamine (acceptor). As a result, the fluorescence
en the labeled liposome and mitochondrial membrane will lead to the diffusion of
uorescence intensity at 530 nm. Scale bars, 10 μm.
Fig. 7. Statistical analysis of the membrane fusion activity of MITO-Porter on and outside mitochondria. Based on images observed by spectral imaging fluorescence
microscopy, as shown in Fig.6, the relative intensity, which represents the fraction of membrane fusion, was calculated as described in Materials and methods. Bars
represent the mean values (n=20). Asterisks indicate significant differences determined by the Student's t-test (pb0.001). A, Relative intensity of MITO-Porter (SM)
[R8-DOPE/SM-LP] and R8-EPC/SM-LP on mitochondria are shown. B, Relative intensity of MITO-Porter (SM) [R8-DOPE/SM-LP] on and outside mitochondria are
shown.
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this study, we applied this method to evaluate membrane fusion.
Liposomal membranes were labeled with both NBD–DOPE
(excitation at 460 nm and emission at 534 nm) and rhodamine–
DOPE (excitation at 550 nm and emission at 590 nm) so that
energy transfer will occur from NBD to rhodamine. As shown
in Fig. 6, the fluorescence intensity at 530 nm increased
significantly, which indicated reduction of energy transfer due
to fusion between the liposomal and mitochondrial membranes
in the case of MITO-Porter. On the other hand, no such increase
at 530 nm was detected in the case of R8-EPC-LP both on the
surface and outside the mitochondria.
We next estimated the relative intensity as described in
Materials and methods to statistically evaluate membrane fusion
of MITO-Porter and R8-EPC-LP on and outside the mitochon-
dria (Fig. 7). On mitochondria, MITO-Porter showed higher
fusogenic activities than R8-EPC-LP (Fig. 7A). Moreover,
MITO-Porter could efficiently induce membrane fusion on the
mitochondria compared with outside themitochondria (Fig. 7B).
These results are consistent with our concept that MITO-Porter
can deliver macromolecules into mitochondria via membrane
fusion in living cells.
4. Discussion
A variety of peptides called protein transduction domains
(PTDs), such as human immunodeficiency virus (HIV-1) TAT-
(48-60) and Antennapedia-(43–58), have been reported to
efficiently deliver biologically active agents to a variety of cells
[34–36]. PTDs have been employed to deliver oligonucleotides,
peptides, and full-length proteins [37]. Moreover, V.P. Torchilin
et al. recently demonstrated that certain TAT-linked liposomes,
even with a diameter of 200 nm, could be efficiently inter-
nalized into a variety of cell lines in intact form [38]. Recently
published reports suggest that the arginine residues of the TATpeptide play a critical role in enhancing the cellular uptake of
TAT, and arginine homopolymers exhibited higher transduction
efficiency than the TAT peptide [39–41]. These findings have
led to increased focus on arginine homopolymers and synthetic
peptide analogues of arginine as transduction domains such as
R7 [39], R8 [41,42], R9 [40,43], and R11 [44–46].
S. Futaki et al. reported that R8 delivered exogenous protein
into cells as efficiently as TAT peptide based on the fluorescence
microscopic observation of the fluorescein-labeled peptides
[41]. Moreover, they showed that these peptides internalized
into cells within 5 min, with little inhibition of uptake at 4 °C,
suggesting that these peptides share a similar in internalization
mechanism, which is macropinocytosis, a clathrin-independent
endocytosis [41,42]. We also showed that high-density R8-LPs
are taken up mainly through macropinocytosis, and delivered to
the cytosol retaining the aqueous phase marker [18]. Based on
these previous reports, R8 was chosen as a cytosol delivery
device for MITO-Porter.
As shown in Fig. 4, R8-EPC-LP could not deliver cargos to
mitochondria in living cells. In this paper, we insisted on mito-
chondrial membrane fusion as an important factor for mito-
chondrial delivery. However, failure of mitochondrial delivery
by R8-EPC-LP might result from something other than a lack of
mitochondrial membrane fusion. To achieve mitochondrial
delivery in living cells, the carrier must be internalized into cell
(i). Thereafter, intracellular trafficking of the carrier including
endosomal escape (ii) and subsequent mitochondrial delivery
(iii), must be accomplished. If these processes were inhibited by
EPC lipid, then R8-EPC-LP could not achieve mitochondrial
delivery. Here, we discuss these points as follows.
First, we were concerned about the possibility that EPC might
prevent cellular uptake of R8. We previously reported that
macropinocytosis is the major entrance pathway for high-density
R8-LPs and that the lipid composition had no effect on the
internalization mechanism [18]. Therefore, we have recognized
431Y. Yamada et al. / Biochimica et Biophysica Acta 1778 (2008) 423–432that efficiencies of cellular uptake of MITO-Porter and R8-EPC-
LP are similar. Second, in general, liposomes including DOPE
can escape from the endosome more efficiently than those
including EPC [47]. However, modificationwith a high density of
R8 causes liposomes to internalize into cells mainly through
macropinocytosis and enhances endosomal escape even in the
case of low fusogenic liposomes [18]. Third, EPC significantly
reduced mitochondrial membrane fusion activity in the case of
isolated mitochondria, as shown in Fig. 2. This result suggested
that EPC could inhibit membrane fusion with mitochondria in
living cells. Therefore, we concluded that EPC drastically in-
hibitedmembrane fusionwithmitochondria and partially lowered
endosomal escape, and that these factors are likely to be involved
in the low level of mitochondrial delivery in living cells.
MITO-Porter contained R8, which has a positive charge.
Therefore, MITO-Porter might be rapidly eliminated from the
systemic circulation after intravenous administration, owing to
the high rate of clearance by the reticuloendothelial system
(RES) or other organs, as also found with cationic liposomes
[48,49]. It is generally accepted that extended circulation can be
achieved by the surface modification of carriers with poly
(ethylene glycol) (PEG) [49,50]. However, PEG is undesirable
during cellular uptake and subsequent processes [51]. We have
recently reported the development of a PEG–Peptide–DOPE
conjugate (PPD) for cancer gene therapy in vivo [52]. In this
strategy, the PEG is removed from the carriers via cleavage by a
matrix metalloproteinase, which is specifically expressed in
tumor tissues. In vivo studies revealed that the PPD was po-
tent in stabilizing the carriers in the systemic circulation and
facilitating tumor accumulation. Moreover, the intravenous
administration of PPD-modified gene carrier resulted in the
stimulation of gene expression in tumor tissue. In the future, we
will attempt to develop a mitochondrial delivery system for
intravenous administration using PPD-modified MITO-Porter.
In this study, we described a liposome-based carrier system
named MITO-Porter which can deliver macromolecules into
mitochondria via a membrane fusion mechanism. Entry of the
intact carriers into cells is stimulated by R8 on the surface of the
MITO-Porter, and delivery into mitochondria is facilitated by the
MITO-Porter's fusogenic lipid composition. Delivery of macro-
molecular cargoes to mitochondria was evaluated by confocal
laser scanning microscopy and transmission electron microscopy.
FRET analysis using spectral imaging fluorescence microscopy
indicated that MITO-Porter delivery occurs via a membrane
fusion mechanism in living cells. These results demonstrated
the principle of our mitochondrial delivery system, which could
lead to development of a novel drug carrier. In the future, we will
attempt to improve MITO-Porter in terms of mitochondrial
targeting efficiency and in vivo delivery formitochondrial diseases
therapy. Studies directed at these goals are currently in progress.
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